What Does Mounjaro Do in the Body? Dual GIP & GLP-1 Action Explained

Key Takeaways:

• Mounjaro (tirzepatide) is the first dual-incretin therapy that activates both GLP-1 and GIP receptors simultaneously.
• In the brain and digestive tract, it dampens persistent food noise, amplifies mealtime fullness, and slows gastric emptying so smaller meals satisfy longer.
• Metabolically, it enhances glucose-dependent insulin sensitivity and lipid handling—driving up to 20%–22.5% average weight reduction in 72-week clinical trials.
• Weekly subcutaneous dosing starts at 2.5 mg for 4 weeks and steps up gradually in 2.5 mg increments only as needed up to 15 mg.

How Dual GIP and GLP-1 Receptor Activation Works

After you eat, your gut naturally releases incretin hormones—GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—to signal fullness and coordinate blood-sugar balance. While earlier medications like semaglutide target GLP-1 alone, tirzepatide mimics both hormones at once:

• Hypothalamic appetite regulation: Calms hunger signaling and reduces reward-driven cravings (‘food noise’).
• Delayed gastric emptying: Slows how rapidly food exits the stomach, extending physical satiety between meals.
• Metabolic & insulin synergy: Stimulates insulin release only when blood glucose is elevated, suppresses excess glucagon, and improves adipose tissue insulin sensitivity.

Clinical Weight-Loss Outcomes and Weekly Titration

In landmark 72-week clinical trials of adults with obesity, once-weekly tirzepatide paired with nutrition and movement changes delivered up to 20%–22.5% average body-weight reduction at higher maintenance doses.

Treatment always begins with a 2.5 mg once-weekly starter dose injected subcutaneously into the abdomen, thigh, or upper arm for 4 weeks. From there, your clinician can maintain a working dose or step up in 2.5 mg increments (5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg) at minimum 4-week intervals.

Expected Adjustment Effects

Most side effects—mild nausea, looser stools, constipation, or heartburn—are digestive, peak briefly after starting or stepping up a dose, and ease with smaller, low-grease meals and steady hydration. Explore whether dual-agonist or GLP-1 care fits your health profile at Amble Weight Loss.